Matushansky Igor 4

What Happened
Igor Matushansky, Chief Medical Officer of Immuneering Corp (IMRX), was granted a derivative award covering 140,000 shares reported on Feb 3, 2026. The Form 4 shows an acquisition of 140,000 shares at $0.00 (derivative)—reported monetary amount $0—indicating a compensation equity award (an option), not an open-market purchase or sale.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (appears timely).
• Transaction type: Grant / award of a derivative (option) — reported as code A.
• Quantity: 140,000 share-equivalents acquired; reported price $0.00 and reported value $0.
• Vesting: Per footnote, the option vests and becomes exercisable in equal monthly installments over four years beginning Feb 1, 2026, and fully vests on Jan 1, 2030.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication in this filing that options were exercised or shares sold.

Context
This is a standard equity compensation grant to an executive rather than a market purchase or sale. As a derivative (option) award, it conveys the right to acquire shares subject to the stated vesting schedule; it does not represent immediate ownership of freely tradable shares. Such grants are commonly used to align executive incentives with long-term company performance.